✦ LIBER ✦

Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells

✍ Scribed by Lev, D C; Kim, L S; Melnikova, V; Ruiz, M; Ananthaswamy, H N; Price, J E

Book ID: 109998206
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 194 KB
Volume: 91
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6602051

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Placental growth factor (PlGF) enhances

Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement

✍ Taylor, A P; Leon, E; Goldenberg, D M 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 582 KB

AP-1 blockade inhibits the growth of nor

AP-1 blockade inhibits the growth of normal and malignant breast cells

✍ Ludes-Meyers, John H; Liu, Yongmin; Muñoz-Medellin, Debbie; Hilsenbeck, Susan G; 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 266 KB

Inhibition of AP-1 transcription factor

Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth

✍ Liu, Yongmin; Ludes-Meyers, John; Zhang, Yun; Munoz-Medellin, Debbie; Kim, Hee-T 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 383 KB

Cell-type-specific roles of IGF-1R and E

Cell-type-specific roles of IGF-1R and EGFR in mediating Zn2+-induced ERK1/2 and PKB phosphorylation

✍ Nihar R. Pandey; George Vardatsikos; Mohamad Z. Mehdi; Ashok K. Srivastava 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 448 KB

Dual blockade of the Hedgehog and ERK1/2

Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells

✍ Artit Jinawath; Yoshimitsu Akiyama; Banchob Sripa; Yasuhito Yuasa 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 366 KB

Response to dual blockade of epidermal g

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor

✍ Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Fakhara Ahmed; Antoinette Wozn 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR‐TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)‐2